Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies
Open Access
- 25 April 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 851825
Abstract
Collagen VI-related dystrophies (COL6-RDs) are a group of rare congenital neuromuscular dystrophies that represent a continuum of overlapping clinical phenotypes that go from the milder Bethlem myopathy (BM) to the severe Ullrich congenital muscular dystrophy, for which there is no effective treatment. Mutations in one of the three Collagen VI genes alter the incorporation of this protein into the extracellular matrix (ECM), affecting the assembly and the structural integrity of the whole fibrillar network. Clinical hallmarks of COL6-RDs are secondary to the ECM disruption and include muscle weakness, proximal joint contractures, and distal hyperlaxity. Although some traits have been identified in patients’ ECMs, a correlation between the ECM features and the clinical phenotype has not been established, mainly due to the lack of predictive and reliable models of the pathology. Herein, we engineered a new personalized pre-clinical model of COL6-RDs using cell-derived matrices (CDMs) technology to better recapitulate the complexity of the native scenario. We found that CDMs from COL6-RD patients presented alterations in ECM structure and composition, showing a significantly decreased Collagen VI secretion, especially in the more severe phenotypes, and a decrease in Fibrillin-1 inclusion. Next, we examined the Collagen VI-mediated deposition of Fibronectin in the ECM, finding a higher alignment, length, width, and straightness than in patients with COL6-RDs. Overall, these results indicate that CDMs models are promising tools to explore the alterations that arise in the composition and fibrillar architecture due to mutations in Collagen VI genes, especially in early stages of matrix organization. Ultimately, CDMs derived from COL6-RD patients may become relevant pre-clinical models, which may help identifying novel biomarkers to be employed in the clinics and to investigate novel therapeutic targets and treatments.Keywords
Funding Information
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (RTI2018-097038-B-C21)
- Instituto de Salud Carlos III
- 'la Caixa' Foundation
- H2020 Marie Skłodowska-Curie Actions
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina
- Ministerio de Ciencia, Innovación y Universidades
- FP7 People: Marie-Curie Actions
- Generalitat de Catalunya
This publication has 68 references indexed in Scilit:
- Gene Expression Profiling Identifies Molecular Pathways Associated with Collagen VI Deficiency and Provides Novel Therapeutic TargetsPLOS ONE, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- ColVI myopathies: where do we stand, where do we go?Skeletal Muscle, 2011
- Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrinsBMC Cancer, 2009
- Fibrillin Assembly Requires FibronectinMolecular Biology of the Cell, 2009
- Stromagenesis During Tumorigenesis: Characterization of Tumor-associated Fibroblasts and Stroma-derived 3D Matrices2009
- Muscle Interstitial Fibroblasts Are the Main Source of Collagen VI Synthesis in Skeletal Muscle: Implications for Congenital Muscular Dystrophy Types Ullrich and BethlemJournal of Neuropathology & Experimental Neurology, 2008
- The molecular genetics of Marfan syndrome and related disordersJournal of Medical Genetics, 2006
- Modulation of collagen fibrillogenesis by tenascin-X and type VI collagenExperimental Cell Research, 2004
- The Epithelial Mitogen Keratinocyte Growth Factor Binds to Collagens via the Consensus Sequence Glycine-Proline-HydroxyprolineJournal of Biological Chemistry, 2002